West Cancer Center

PROSTRATE: METASTATIC: CRPC: 2nd line or later: SWOG S2312

A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

Title

SWOG S2312 Prostate CRPC

Study Title

A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

Site Link

NCT06470243

Malignancy

Prostate, CRPC

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

2nd line or later

Investigational Agent

Carboplatin

Drug Class

platinum chemotherapy

Dan Vaena, MD

Sponsor

SWOG

Phase

Phase 3

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Histologically confirmed CRPC
Metastatic disease confirmed by bone scan or CT/MRI
Any prior therapy but one must be contain docetaxel in the castrate-sensitive or castrate resistant setting
Tumor specimens available
Must have progressive disease from last therapy
No prior receipt of carboplatin or cabazitaxel
No untreated fractures

Objective

Primary
- Radiographic PFS
Secondary
- PSA response
- ALK phos response
- RECIST response
- OS

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Adenocarcinoma

Dosing Frequency

Control Agents

Study Protocol

Randomized

Yes